Literature DB >> 11220764

Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine.

J Fernández1, S Balter, J Feris, E Gómez, Z Garib, P L Castellanos, J Sánchez, S Romero-Steiner, O S Levine.   

Abstract

To assess the immunogenicity of more economical regimens of Haemophilus influenzae type b (Hib) conjugate vaccine, a randomized trial of fractional doses of polyribosylribitol phosphate-tetanus toxoid (PRP-T) Hib vaccine was undertaken in the Dominican Republic. Six hundred children were assigned to one of six regimens with PRP-T vaccine: full-dose, half-dose, and one-third-dose of Hib vaccine given separately or combined with diphtheria, tetanus, and pertussis (DTP) vaccine at ages 2, 4, and 6 months. Regimens that elicited antibody levels > 1.0 microg/mL in >70% of children and < or = 0.15 microg/mL in > 90% of children were considered acceptable. At 1 month post Dose 3, all regimens met the criteria for acceptable response. Among those who received Hib as a separate injection, geometric mean concentrations of anti-PRP bodies (GMCs) at age 1 month post Dose 3 were 11.2, 11.9, and 16.3 in the full, half, and one-third dose groups, respectively. Among those who received Hib and DTP combined, the GMCs were 6.4, 5.2, and 5.7 in the full-, half-, and one-third-dose groups respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11220764     DOI: 10.4269/ajtmh.2000.62.485

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Serological protection induced by Haemophilus influenzae Type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed?

Authors:  Romeo S Rodriguez; Cesar Mascarenas; Carlos J Conde-Glez; Jaime Inostroza; Sonia Villanueva; María Elena Velázquez; Miguel Angel Sánchez-Alemán; Gabriela Echániz
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

2.  Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Authors:  Nadine G Rouphael; Sarah Satola; Monica M Farley; Karen Rudolph; Daniel S Schmidt; Patricia Gomez-de-León; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

3.  Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Authors:  Henry C Baggett; Thomas W Hennessy; Lisa Bulkow; Sandra Romero-Steiner; Debra Hurlburt; Patricia Holder; Alan J Parkinson; Rosalyn J Singleton; Orin Levine; George M Carlone; Jay C Butler
Journal:  Clin Vaccine Immunol       Date:  2006-06

4.  Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).

Authors:  S Romero-Steiner; J Fernandez; C Biltoft; M E Wohl; J Sanchez; J Feris; S Balter; O S Levine; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

5.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

6.  Measurement of Haemophilus influenzae type a capsular polysaccharide antibodies in cord blood sera.

Authors:  Daniel S Schmidt; Kathryn T Bieging; Patricia Gomez-de-León; Alberto Villaseñor-Sierra; Jaime Inostroza; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

7.  The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.

Authors:  Sukanta Chatterjee; Sylvan J Rego; Fulton D'Souza; B D Bhatia; Alix Collard; Sanjoy K Datta; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

8.  Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Authors:  Do Gia Canh; Feng-ying Kimi Lin; Vu Dinh Thiem; Dang Duc Trach; Nguyen Dinh Trong; Nguyen Duc Mao; Steven Hunt; Rachel Schneerson; John B Robbins; Chiayung Chu; Joseph Shiloach; Dolores A Bryla; Marie-Claude Bonnet; Dominique Schulz; Shousun C Szu
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.